Samuel R. Meier
机构：Tango Therapeutics (United States) · ORCID：0000-0002-7026-2722
发表论文 234 篇 · 总被引 24867 次 · h-index 38
代表论文
- Suppressing Phosphatidylserine Externalization Overcomes Cancer Immune Evasion and Enhances Immunotherapy (2026 · Molecular Cancer Therapeutics)
- Table S4 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers (2026)
- Figure S3 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers (2026)
- Table S1 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers (2026)
- Figure 2 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers (2026)
- Figure 4 from TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers (2026)